Hepatitis C Diagnosis and Treatment Market by MRFR Research Report Forecast 2020 – 2025 is a valuable source of insightful data for business strategists
Overview
Hepatitis C is the inflammation of liver caused by infection by hepatitis C virus characterized by a host of symptoms such as yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay coloured stools etc. According to the World Health Organisation, hepatitis C affects between 130–150 million people globally every year claiming a toll of 700000 lives. Of those who recover about 15-20% develop liver cirrhosis or liver cancer.
Market Players
Hoffmann-La Roche Ltd (Switzerland), BMS (U.S), Merck & Co., Inc (U.S), Vertex Pharmaceuticals Incorporated (U.S), Gilead sciences Inc (U.S.)., Abbvie Inc (U.S.), Johnson & Johnson (U.S.), Glaxosmithkline plc (U.K), Novartis AG (Switzerland), Bristol-Myers Squibb (U.S.) are some of the prominent players at the forefront of competition in the Hepatitis C Diagnosis and Treatment Market and are profiled in MRFR Analysis.
According to Centres for Disease Control & Prevention, in U.S., liver cancer incidence is increasing at a rapid rate (2.3 % per year overall from 2003 – 2012), second only to thyroid cancer. Moreover, the rate of deaths due to liver cancer is increasing faster than for any other type of cancer. Furthermore, Hepatitis B and C are major contributing factors to liver cancer.
According to American Cancer Society, Worldwide, the most common risk factor for liver cancer is chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). These infections lead to cirrhosis of the liver and are responsible for making liver cancer the most common cancer globally.
The market for hepatitis C diagnosis & treatment is driven by factors such as increasing prevalence of liver cancer, rise in government subsidy and reimbursement especially in U.S., greater screening especially in developing nations, drug abuse and unsafe sex etc. On the other hand, the market constraining factors are self-imitating nature of the disease in a sizable number of patients, challenge of herbal treatment offered at negligible prices especially in developing regions, price war between companies such as between Gilead and Merck, rising urbanization and better sanitation etc.
Global Hepatitis C Diagnosis and Treatment Market-Competitive Analysis
October, 2013 - Janssen (Parent organisation Johnson & Johnson Services, Inc.) acquired investigational NS5A Inhibitor for the treatment of Hepatitis C from GlaxoSmithKline. According to company reports, GSK2336805 is an investigational NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis.
October, 2013 - Bristol-Myers Squibb to presented range of new Hepatitis C data at the 2013 American Association for the Study of Liver Diseases (AASLD). According to company reports, Bristol-Myers Squibb’s hepatitis C includes compounds with different mechanisms of action, biologics as well as small molecule direct-acting antivirals. These compounds were being studied as part of multiple treatment regimens with the goal of increasing SVR rates across different patient types. Moreover, company stated NS5A replication complex inhibitor daclatasvir (DCV) had been extensively studied in thousands of patients to date as a foundational agent for multiple DAA-based combination therapies and is currently in Phase III development.
DCV has shown antiviral potency and pan-genotypic activity across HCV genotypes in vitro. DCV has a drug-drug interaction profile that supports its continued study in a variety of HCV combination regimens. However, Asunaprevir (ASV) is an NS3 protease inhibitor in Phase III development for hepatitis C as a component of DCV-based treatment regimens. BMS-791325 is a non-nucleoside inhibitor of the NS5B polymerase, currently in Phase II development for hepatitis C as a component of DCV-based treatment regimens. Lambda is an investigational type III interferon that has the potential to offer an alternative to alfa-interferon in patients for whom an interferon-based regimen is required or preferred.
Global Hepatitis C Diagnosis and Treatment Market- Regional Analysis
Depending on geographic region, Hepatitis C diagnosis & treatment market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally, Americas is the largest market for global Hepatitis C diagnosis and treatment with Europe in the second position. However, the developed regions market is stagnant and will continue to do so with Asia Pacific region particularly India and China rising fast. Asia pacific region is expected to be fastest growing region in hepatitis C diagnosis & treatment market. The African region is expected to be a laggard and will show at most a moderate rate of growth.
Browse Full Report @ https://www.marketresearchfuture.com/reports/hepatitis-c-diagnosis-treatment-market-1569
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact
https://www.marketresearchfuture.com
“Global Hepatitis C Diagnosis and Treatment Market Research Report – Forecast to 2025” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2025.Global Hepatitis C Diagnosis and Treatment Market – OverviewHepatitis C is the inflammation of liver caused by infection by hepatitis C virus characterized by a host of symptoms such as yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay coloured stools etc.
According to the World Health Organisation, hepatitis C affects between 130–150 million people globally every year claiming a toll of 700000 lives.
Furthermore, Hepatitis B and C are major contributing factors to liver cancer.Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/1569According to American Cancer Society, Worldwide, the most common risk factor for liver cancer is chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
These infections lead to cirrhosis of the liver and are responsible for making liver cancer the most common cancer globally.
Global Hepatitis C Diagnosis and Treatment Market-Competitive AnalysisHoffmann-La Roche Ltd (Switzerland), BMS (U.S), Merck & Co., Inc (U.S), Vertex Pharmaceuticals Incorporated (U.S), Gilead sciences Inc (U.S.)., Abbvie Inc (U.S.), Johnson & Johnson (U.S.), Glaxosmithkline plc (U.K), Novartis AG (Switzerland), Bristol-Myers Squibb (U.S.) are some of the prominent players at the forefront of competition in the Global Hepatitis C Diagnosis and Treatment Market and are profiled in MRFR Analysis.October, 2013 – Janssen (Parent organisation Johnson & Johnson Services, Inc.) acquired investigational NS5A Inhibitor for the treatment of Hepatitis C from GlaxoSmithKline.
According to company reports, GSK2336805 is an investigational NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis.October, 2013 – Bristol-Myers Squibb to presented range of new Hepatitis C data at the 2013 American Association for the Study of Liver Diseases (AASLD).
OverviewThe growing incidence of diabetes and its effects has led to advances in technology for its management.
The global digital diabetes management market report by Market Research Future (MRFR) contained valuable insights and predictions for the period of 2018 to 2027 (forecast period).Market ScopeThe global digital diabetes management market is anticipated to exhibit 23.7% CAGR during the forecast period.
Rising awareness of preventive care and prevalence of obesity can lead to a higher uptick in the demand of digital diabetes management applications.However, strict regulations pertaining to approval of applications and devices can hamper market growth.Get Request Free Sample @ https://www.marketresearchfuture.com/sample_request/7527SegmentationThe global digital diabetes management market has been segmented by type, product and services, and end user.By type, the market is divided into wearable devices and handheld devices.
The wearable devices segment is expected to hold the largest market share of the digital diabetes management market during the forecast period owing to regulatory approval of advanced products and technological advancements such as smart insulin patches.By product and service, it is segmented into digital diabetes management apps, data management software and platforms, devices, and services.
Devices consist of smart insulin pumps/closed loop systems & smart insulin patches, smart glucose meters, smart insulin pens, and continuous glucose monitoring systems.
Recently, Oviva a Swiss-based provider of digital solutions for diabetes has raised close to USD 21 million in funding.Competitive OutlookTandem Diabetes Care, Inc., Glooko, Inc., Agamatrix, Inc., Insulet Corporation, Ascensia Diabetes Care Holdings Ag., B. Braun Melsungen AG, Medtronic PLC, F. Hoffmann-La Roche, Dariohealth Corporation, Dexcom, Inc., Abbott Laboratories, Tidepool, Lifescan, Inc., and others are major players of the global digital diabetes management market.Browse Complete Report @ https://www.marketresearchfuture.com/reports/digital-diabetes-management-market-7527 About Market Research Future:At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half- Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Total diabetic population in China is 113 million, which accounts 11% of total Chinese population, whereas 67 million people in India have diabetes.
According to a study, China has the highest smoking rate and smoking increases the chances of developing diabetes by 45% as compare to non-smoker, which, in turn, will drive the growth of the market over the assessment period.Free sample copy is available here @ https://www.marketresearchfuture.com/sample_request/625Market PlayersHoffmann-La Roche Ltd (Switzerland), Abbott (US), LifeScan, Inc. (US), i-SENS.
Inc. (South Korea), AgaMatrix (US), TaiDoc Technology Corporation (Taiwan), BioSensors, Inc. (US), Universal Biosensors (Australia), Beijing Yicheng Electronic Co., Ltd (China), Hmd Biomedical (Taiwan), and B. Braun Melsungen Ag (Germany).Many countries in Asia Pacific are developing rapidly.
Majority of the population in Asia Pacific region smoke, which is another factor responsible for development of diabetes.
Different types of test are available to monitor the blood glucose level such as oral glucose tolerance test, postprandial blood sugar, random blood sugar testing, and others.
SegmentationAsia Pacific blood glucose test strip market is segmented on basis of types, technology and end users.On the basis of types, the market is segmented into glucose oxidase, glucose dehydrogenase, and other.On the basis of technology, the market is segmented into wicking technology and channel technology.On the basis of end user, the market is categorised in hospital, clinic, homecare, and othersRegional AnalysisAsia Pacific region is segmented into Japan, China, India, Australia, Republic of Korea, and Rest of Asia Pacific.
Market SynopsisMarket Research Future (MRFR) postulates that the biosimilars market is predicted to garner USD 3.35 billion, grabbing a CAGR of 26% throughout the forecast period (2017-2023).
They are generally derived from a plant, bacteria, yeast, and other several processes.
They are produced by two main processes, recombinant DNA technology and controlled gene expression.Market Potential and PitfallsWith the augmenting incidences of several chronic diseases, growing demand for cheap medical products, and strategic collaborations leading to clinical trials and enhanced productivity, the global biosimilars market is estimated to flourish throughout the appraisal period.
Biosimilars are extensively used in the treatment and prevention of chronic diseases like cancer, diabetes, autoimmune disease, cardiovascular diseases (CVDs), kidney failure, rheumatoid arthritis, hematological disease, hormone growth deficiency, and infectious disease.
Moreover, different private and government bodies are promoting the use of biosimilars over synthetic drugs and conventional biologics, which is further propelling the growth of the market across the globe.
Also, with the rapid growth in the pharmaceutical sector combined with the high cost of existing biological drugs, the market is anticipated to boom.
Demand for Hepatitis C Treatment Expected to Remain High in North America during 2016-2024According to a recent study conducted by RRI, the global market forhepatitis C treatment is expected to expand at a CAGR of over 13% during the forecast period (2016-2024).
By the end of 2016, market is anticipated to stand at US$ 26.6 and is estimated to surpass US$ 71 Billion by 2024.Factors such as higher per capita healthcare expenditure worldwide and growing prevalence of hepatitis C infections in countries such as U.S. and Canada is expected to drive the global market for global hepatitis C treatment during the forecast period.
On the other hand, expensive drugs for hepatitis C treatment and lack of awareness about hepatitis C infection amongst the people in developing regions across the globe may inhibit the growth of the market during the forecast period.Request For Report Sample: https://www.researchreportinsights.com/report/sample/110114958/Hepatitis-C-Treatment-Market On the basis of drugs, the global market for hepatitis C treatment has been segmented into HCV NS5A inhibitors, HCV protease inhibitors, interferon & antiviral, HCV polymerase inhibitors, and combination therapy.
The segment is expected to expand at a CAGR of over 13% during 2016-2024.On the basis distribution channel, the market has been segmented into online pharmacies, hospital pharmacies and retail pharmacies.
Hospital pharmacy is expected to be the most dominant segment during the forecast period.
The growth of the segment is due to ample stock of hepatitis C treatment drugs with added discount offered by online drug pharmacies.Request Report Discount: https://www.researchreportinsights.com/report/discount/110114958/Hepatitis-C-Treatment-Market On the basis of region, North America is expected to be the leading market for hepatitis C treatment, estimated to account for 45% share by the end of 2016.
Global Chemotherapy Market: Information by Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors and Antitumor Antibiotic), Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Leukemia and Ovarian Cancer), Route of Drug Administration (Intravenous, Oral, Subcutaneous, Intra-Muscular, Intravesicular, Topical, Intraperitoneal and Intraventricular/Intrathecal) and End-User (Specialty Centers and Hospitals & Clinics) - Global Forecast till 2027Chemotherapy is one of the most trustworthy methods used during the treatment of cancer.
The global chemotherapy market report compiled by Market Research Future (MRFR) contains a quantitative and qualitative analysis of drivers, trends, opportunities, and challenges.Market OutlookThe global chemotherapy market size is likely to touch a size of USD 56,491.59 million by 2024 by showcasing a CAGR of 11.50% from 2019 to 2024 (forecast period).
The number is high in countries dealing with changing lifestyles as well as rapid industrialization.Rising health expenditure dedicated for oncology, attractive reimbursement schemes for patients, and rise in number of health insurance schemes are drivers of the market.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5791Segmentation AnalysisThe global chemotherapy market is segmented by route of drug administration, drug class, indication, and end-user.By route of drug administration, it is segmented into intraventricular/intrathecal, intravesicular, intra-muscular, intravenous, intraperitoneal, topical, oral, and subcutaneous.
Intravenous accounted for the largest market share, but the oral segment can exhibit 11.95% CAGR to accumulate significant revenue till 2024.By drug class, it is segmented into antitumor antibiotic, mitotic inhibitor, topoisomerase inhibitor, antimetabolites, and alkylating agents.
The alkylating agent segment is likely to exhibit 11.83% CAGR during the forecast period to reach a value of USD 20,360.32 million by 2024.By indication, it is segmented into colorectal cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, stomach cancer, leukemia, lymphoma, and others.
On the other hand, breast cancer can exhibit 11.94% CAGR during the aforementioned period.By end-user, it is segmented into hospitals & clinics, specialty centers, and others.Regional AnalysisThe Middle East & Africa, Asia Pacific (APAC), the Americas, and Europe are regions taken into consideration in the compilation of the global chemotherapy market report.The Americas accounted for a market share exceeding 40% in 2018 and can register 10.88% CAGR during the forecast period.
